The South Korean biotechnology sector, which achieved record technology exports last year, is showing resilience in the first half of 2026 with a series of significant contracts. As major conferences and partnering events are set to commence in the latter half of the year, attention is focused on whether additional large deals will follow on the global stage.
As of mid-May, the scale of technology transfers in the domestic biotech industry reached $6.5 billion, about half of last year's total of $13.7 billion, based on maximum milestone criteria. Although the number of technology transfer agreements stands at five—down from 14 last year—the value per contract has been substantial.
Aribio and Alteogen have been at the forefront this year. Aribio secured a global licensing deal for AR1001 with China's Puxing Pharmaceutical, generating $4.7 billion. Earlier, Alteogen signed a contract worth approximately $285 million with GSK subsidiary Tesaro in January and another deal with Biogen valued at $569 million in March.
An industry insider noted, "Western big pharma companies are seeking reliable platform technologies, while large Chinese pharmaceutical firms are looking for differentiated substances to aid their global expansion, leading to continued interest in South Korean biotech firms." However, investment sentiment in the biotech sector has been low in the first half of the year.
Huh Hyemin, a researcher at Kiwoom Securities, stated, "The controversy over royalty rates, clinical data issues, and contract-related disputes have shaken overall confidence in the biotech sector." Nevertheless, the second half of the year presents opportunities for recovery, as major global conferences and partnering events will kick off at the end of May.
Key events include the European Association for the Study of the Liver (EASL) on May 27, the American Society of Clinical Oncology (ASCO) on May 29, the American Diabetes Association (ADA) next month, the BIO International Convention at the end of June, and the European Society for Medical Oncology (ESMO) in October.
These conferences are seen as more than just platforms for research presentations; they are considered practical venues for technology transfers. Promising candidate substances will have their clinical data disclosed, often leading to business development meetings with global pharmaceutical companies and accelerating licensing negotiations.
Huh added, "The number of oral presentations by domestic companies at major global conferences is increasing, and this year’s focus has shifted from preclinical to clinical data. This indicates that South Korean biotech firms are moving beyond merely holding early-stage technologies to accumulating clinical data that allows for discussions on global commercialization."
At ASCO, companies such as GI Innovation, VigenCell, and Lunit will present their findings. Among them, GI Innovation's GI-101A is a pipeline aimed at technology transfer, and positive data could increase the likelihood of follow-up negotiations.
A pharmaceutical industry representative remarked, "If the flow of data presentations leads to actual technology transfers, it could restore and reassess the confidence that has been dampened in the biotech sector."
As of mid-May, the scale of technology transfers in the domestic biotech industry reached $6.5 billion, about half of last year's total of $13.7 billion, based on maximum milestone criteria. Although the number of technology transfer agreements stands at five—down from 14 last year—the value per contract has been substantial.
Aribio and Alteogen have been at the forefront this year. Aribio secured a global licensing deal for AR1001 with China's Puxing Pharmaceutical, generating $4.7 billion. Earlier, Alteogen signed a contract worth approximately $285 million with GSK subsidiary Tesaro in January and another deal with Biogen valued at $569 million in March.
An industry insider noted, "Western big pharma companies are seeking reliable platform technologies, while large Chinese pharmaceutical firms are looking for differentiated substances to aid their global expansion, leading to continued interest in South Korean biotech firms." However, investment sentiment in the biotech sector has been low in the first half of the year.
Huh Hyemin, a researcher at Kiwoom Securities, stated, "The controversy over royalty rates, clinical data issues, and contract-related disputes have shaken overall confidence in the biotech sector." Nevertheless, the second half of the year presents opportunities for recovery, as major global conferences and partnering events will kick off at the end of May.
Key events include the European Association for the Study of the Liver (EASL) on May 27, the American Society of Clinical Oncology (ASCO) on May 29, the American Diabetes Association (ADA) next month, the BIO International Convention at the end of June, and the European Society for Medical Oncology (ESMO) in October.
These conferences are seen as more than just platforms for research presentations; they are considered practical venues for technology transfers. Promising candidate substances will have their clinical data disclosed, often leading to business development meetings with global pharmaceutical companies and accelerating licensing negotiations.
Huh added, "The number of oral presentations by domestic companies at major global conferences is increasing, and this year’s focus has shifted from preclinical to clinical data. This indicates that South Korean biotech firms are moving beyond merely holding early-stage technologies to accumulating clinical data that allows for discussions on global commercialization."
At ASCO, companies such as GI Innovation, VigenCell, and Lunit will present their findings. Among them, GI Innovation's GI-101A is a pipeline aimed at technology transfer, and positive data could increase the likelihood of follow-up negotiations.
A pharmaceutical industry representative remarked, "If the flow of data presentations leads to actual technology transfers, it could restore and reassess the confidence that has been dampened in the biotech sector."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.